#3 - CureVac (NASDAQ:CVAC)
CureVac N.V. (NASDAQ: CVAC) is the third and last of the biotech companies on this list of stocks under $20 that have a chance of doubling in the next 18 months. Although the mRNA technology used to develop two of the Covid-19 vaccines remains controversial, there’s no question that it is changing the way some vaccines will be developed in the future.
CuraVac was not successful in developing a Covid-19 vaccine, but it is still a leader in mRNA technology and will continue to use that in its development process. For example, the company recently tested its first patient in a Phase 1 study for an mRNA-based cancer vaccine targeting brain tumor glioblastoma. As anyone who has had a loved one with this type of cancer knows, there is no cure and the prognosis, while expanding, is poor.
The company’s expertise in mRNA puts the risk and reward in plain sight for investors. And with a company that’s not yet profitable, there is always risk involved. But analysts suggest the stock may gain 102% in the next 12 months, which makes it a speculative buy for the right investor.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Read More - Current Price
- $2.56
- Consensus Rating
- Hold
- Ratings Breakdown
- 1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $10.00 (290.6% Upside)
